Comments on the increasing use of molecular imaging (MI) in drug development in the U.S. Impact of research on the potential of MI to improve drug development; Effect of the cost of drug development on the adoption of innovations; Overview of several companies that have added imaging capabilities to their drug development tools, including GlaxoSmithKline PLC; Efforts of medical instrument manufacturers to expand their imaging offerings.